Accueil>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>TH588 hydrochloride

TH588 hydrochloride

Catalog No.GC37777

Le chlorhydrate de TH588 est le premier inhibiteur de la famille des hydrolases nudix qui engage et inhibe de manière puissante et sélective le MTH1 (IC50 = 5 nM).

Products are for research use only. Not for human use. We do not sell to patients.

TH588 hydrochloride Chemical Structure

Cas No.: 1640282-30-9

Taille Prix Stock Qté
5mg
70,00 $US
En stock
25mg
130,00 $US
En stock
50mg
234,00 $US
En stock
100mg
422,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TH588 hydrochloride is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC50= 5 nM).

TH588 (2-10μM; 7-10 days) selectively and effectively kills U2OS, HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells with IC50s of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 μM [1]. Cell Viability Assay[1] Cell Line: U2OS, HeLa, MDA-MB-231, MCF-7, SW480, SW620, VH10, HDFn cells

TH588 (30 mg/kg; s.c.; once daily for 35 days) reduces tumour growth in SW480 xenograft cancer model[1]. Animal Model: 5-6 weeks female SCID mice (SW480 xenograft cancer model)[1]

[1]. Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21.

Avis

Review for TH588 hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TH588 hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.